Reagent Problem Could Have Affected Rosetta Genomics' Cancer Test Results

In a document filed with the SEC, the Israeli firm disclosed that problems with a reagent used for testing could have affected results for about 100 miRview mets tests performed in the company's CLIA laboratory between August and October.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.